Share:
MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L Huillier brings over two decades of experience in executive leadership positions in the pharmaceutical and biotechnology industries, with an outstanding track record of success in the commercial development of businesses and partnerships. His experience reflects an international career in business, science, and academia.
Dr. Phil L Huillier joins CatalYm from a position as Head of the European Innovation Hub & Business Development at MSD (known as Merck & Co. in North America). In this position he was an active member of MSD global Business Development and Licensing Leadership as well leading a team of scientific and business development professionals that were focused on the identification, evaluation and development of
CatalYm Appoints Industry Leader Dr. Phil L'Huillier as Chief Executive Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Novartis, Artios cancer discovery deal worth up to $1.3bn outsourcing-pharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outsourcing-pharma.com Daily Mail and Mail on Sunday newspapers.